Newsroom

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

1 min read

Selexis SA CEO to Speak at the BioProcess Theater at BIO 2014

May 30, 2014 2:50:27 PM

Dr. Igor Fisch to Present Data on Using Genome Engineering and the Selexis SURE CHO-Mplus Libraries for Optimal Transgene Expression and Recombinant Protein Production

Geneva, Switzerland, May 30, 2014 – Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development announced today the Company’sCEO, Igor Fisch, PhD, will present “Genome Engineering and SURE CHO-Mplus Libraries™ for Optimal Transgene Expression andRecombinant Protein Production” at the BioProcess Theater on June 24, 2014 at 2:30 PM. The BioProcess Theater presentations are part of the BIO International Convention being held Jun 23-26 in San Diego, California at the San Diego Convention Center.

Presentation Abstract:

Based on proprietary epigenetic DNA regulator elements and leveraging the SURE CHO-M Genome and Transcriptome, Selexis has developed a novel platform approach for the generation of CHO cell lines. By combining robust transcription with a library approach to debottlenecking translation, folding and secretion, Selexis has launched the SURE CHOM-Mplus™ Libraries. This technology has an extensive history of generating high-level, stable expressing cell lines, including cell lines producing difficult-to-express proteins such as Fc-fusions and large multimeric proteins. The extensive characterization of the CHO-M cell line supports comprehensive and effective transfer packages for manufacturing.


Igor Fisch, PhD, CEO of Selexis headshot


Igor Fisch, PhD, CEO of Selexis
"This technology has an extensive history of generating high-level, stable expressing cell lines, including cell lines producing difficult-to- express proteins such as Fc-fusions and large multimeric proteins."
Topics: 2014

Featured